Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present
Molecular Diagnostics Market worth $31.8 billion by 2026 - Exclusive Report by MarketsandMarkets Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs) - Global Forecast to 2026 , published by MarketsandMarkets, the global market is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a 12.3% CAGR.
Browse in-depth TOC on
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833
The increasing prevalence of infectious diseases and cancer, the rising funding for R&D, the increase in PoC testing devices and technological advancements drives growth in the molecular diagnostics market. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.